¸´·¢ºÍתÒÆÊÇ°©Ö¢ËÀÍöµÄÁ½¸öÖ÷ÒªÔÒò¡£Òò´Ë£¬ÔçÆÚ׼ȷµÄ°©Ö¢Õï¶Ï±ãÏÔµÃÓÈΪÖØÒª¡£Ä¿Ç°£¬ÓÃÓÚ̽²â°©Ö¢µÄ¹¤¾ßÖ÷ÒªÓÐÄÄЩ£¿ÄÉÃ×¼¼ÊõµÄ·¢Õ¹ÓÖΪ°©Ö¢Ì½²â´øÀ´ÄÄЩ½øÕ¹ÄØ£¿
С M Ϊ´ó¼Ò×ܽáÁËÄ¿Ç°°©Ö¢µÄ̽²â¹¤¾ß£¬ÎÒÃÇÏÈÒ»Æð¼òµ¥Á˽âÏ°É~
1. ÓÃÓÚÈ·¶¨°©Ö¢·ÖÆÚ¼°Æ侫ȷλÖõÄһЩ³ÉÏñ¸¨ÖúÊֶΣº
´Å¹²Õñ³ÉÏñ (Magnetic resonance imaging, MRI)¡¢Õýµç×Ó·¢Éä¶Ï²ãɨÃè (Positron emission tomography, PET)¡¢µ¥¹â×Ó·¢Éä¼ÆËã»ú¶Ï²ãɨÃè (Single photon emission computed tomography, SPECT)¡¢¼ÆËã»ú¶Ï²ãɨÃè (Computed tomography, CT) ºÍ¹âѧ³ÉÏñµÈ¡£
2. ¹âѧ³ÉÏñ£ºÓÃÓÚ°©Ï¸°ûÔÚ·Ö×ÓˮƽµÄ¿ÉÊÓ»¯¡£
ÓÃÓÚ¹âѧ³ÉÏñµÄÓ«¹â̽Õë¿ÉÒÔ±»Éè¼Æ³É¿É¼¤»îµÄ£¬ÕâÒâζ×ÅËüÃÇÖ»»áÔÚijЩÌõ¼þÏ¡°´ò¿ª¡±¡£ÕâÖÖ̽Õë±»Éè¼Æ³ÉÖ»ÓÐÔÚÓëÄ¿±ê×éÖ¯½áºÏºó²Å»á·¢³öÐźţ¬Õâ´ó´óÌá¸ßÁ˼ì²â¼²²¡µÄÁéÃô¶ÈºÍÌØÒìÐÔ¡£
3. ´«Í³µÄ³ÉÏñ·½·¨
ÈçѪ¹ÜÔìÓ°¡¢CT¡¢MRI ºÍ·ÅÉäÐÔºËËسÉÏñ£¬ÒÀÀµÓÚÔìÓ°¼Á£¬Èçµâ¡¢îźͷÅÉäÐÔͬλËØ¡£
´ËÍ⣬2023 Ä껯ѧ¼Ò Moungi G. Bawendi¡¢Louis E. Brus ºÍÎïÀíѧ¼Ò Alexei I. Ekimov Òò¡°·¢ÏֺͺϳÉÁ¿×ӵ㡱ÈÙ»ñŵ±´¶û»¯Ñ§½±¡£ÕâʹµÃÓ«¹âÁ¿×Óµã½øÈëÁ˸ü¶àÈ˵ÄÊÓÒ°ÖС£
ͼ 1. 2023 ÄêÈÙ»ñŵ±´¶û»¯Ñ§½±µÄ¿Æѧ¼Ò¡£
Á¿×Óµã (Quantum dots,QDs)£¬Ò»ÖÖ·¢¹âÄÉÃ×¾§Ìå (Nanocrystals, NCs)£¬¿ÉΪÖÎÁÆÒ©Îï¡¢µ°°×ÖÊ¡¢ëÄ¡¢¹ÑºËÜÕËáºÍ»ùÒòµÄÊܿصÝËͺóµÄÉúÎïϵͳ³ÉÏñÌṩ¶à¹¦ÄÜƽ̨¡£ÕâЩ¾ßÓÐ×ۺϳÉÏñºÍÔØÌ幦ÄܵŤ³ÌÓ«¹â̽ÕëÒѳÉΪ·Ö×ÓÕï¶ÏºÍÖÎÁÆ·Ö×ÓµÝË͵ġ°ºÃ°ïÊÖ¡±£¡
ͼ 2. Á¿×Óµã½á¹¹¡£
Tips£º¹ØÓÚÁ¿×ӵ㣬ÄãÐèÒªÁ˽âÄÄЩ£¿
1£©Á¿×ÓµãÊǽüºõÇòÐ뵀 NC£¬Êµ¼ÊÉÏÊÇÓÉ°ëµ¼Ìå²ÄÁÏ×é³ÉµÄ¡£ÕâЩ°ëµ¼ÌåÊÇÓÉ ¢ò¡«¢ö ×å»ò ¢ó¡«V ×åÔªËØ×é³ÉµÄ·¢¹âÄÉÃ×¾§Ì壬һ°ãΪÇòÐλòÀàÇòÐΣ¬Îȶ¨Ö±¾¶ÔÚ 2~10 nm£¬Äܹ»½ÓÊܼ¤·¢¹â²úÉúÓ«¹âµÄÒ»Àà°ëµ¼ÌåÄÉÃ׿ÅÁ£¡£
2£©ÔÚÔªËØÖÜÆÚ±íÖеÄËùÓлùÍÅÖУ¬×îÓÐȤµÄÊÇ II-VI£¬ÒòΪËüÃǾßÓжÀÌصĹâѧºÍµç×ÓÐÔÖÊ¡£°üÀ¨ (CdSe)¡¢ (CdS)¡¢ (CdTe)¡¢ (ZnO)¡¢ (ZnS)¡¢ (ZnSe) ºÍ (ZnTe) µÈ²ÄÁÏ¡£ÆäÖÐÑо¿½Ï¶àµÄÖ÷ÒªÊÇ CdX (x=S¡¢Se¡¢Te)¡£
3£©Á¿×Óµã¾ßÓпíÁ¬ÐøÎüÊÕ¹âÆס¢Õ·¢Éä¹âÆס¢¸ß¹âÎȶ¨ÐԵȶÀÌصķ¢¹âÌØÐԺ͵ç×ÓÌØÐÔ¡£Æä·¢É䲨³¤¿ÉÒÔͨ¹ý¸Ä±äËüÃǵĴóСºÍ×é³ÉÀ´µ÷½Ú (Á¿×Óµã³ß´çµÄ¼õСµ¼ÖÂÄÜ϶µÄÔö´ó£¬µ¼Ö·¢É䲨³¤µÄÀ¶ÒÆ)£¬ÕâÒ²´ú±íµ¥¸ö¹âԴͬʱ¼¤·¢ËùÓÐÑÕÉ«µÄÁ¿×Óµã[1]¡£Òò´ËÁ¿×ÓµãµÄÓ¦ÓÃÊ®·Ö¹ã·º¡£
▐ ½üºìÍâÓ«¹âÌØÐÔ
ÉúÎﻯºÏÎïºÍ×éÖ¯ (ÈçѪҺ¡¢Ö¬·¾ºÍƤ·ô) ¶¼ÄÜÌض¨µØÎüÊÕºÍÉ¢É䲻ͬ³Ì¶ÈµÄÈκÎÈëÉä¹â¡£Òò´Ë¶¯ÎïÌåÄÚµÄ×Ô·¢Ó«¹â±¾Éí»á¸ÉÈűê¼ÇÄ¿±êÓ«¹âЧ¹û£¬II-VI ×åºÍ IV-VI ×åÁ¿×Óµã¾ßÓнüºìÍâÓ«¹âÐÔÖÊ£¬½üºìÍâ ¢ò ÇøÓ«¹â (²¨³¤ 1000~1700 nm) ´æÔÚןü¸ßµÄ¿Õ¼ä·Ö±æÂÊ¡¢¸üÉîµÄ´©Í¸ÉúÎï»ùÖʵÄÉî¶È¡¢½ÏµÍµÄ¹âѧÎüÊÕºÍÉ¢É䣬¿ÉÒԺܺõıÜÃâ»úÌå×Ô·¢Ó«¹â¸ÉÈÅ[2]¡£
ͼ 3. ´ú±íÐÔµÄÁ¿×ÓµãºËÐIJÄÁϵķ¢É䲨³¤ÐźÅ[2]¡£ £¨A£©´ú±íÐÔµÄÁ¿×ÓµãºËÐIJÄÁÏ×÷ΪÆä·¢É䲨³¤µþ¼ÓÔÚ¹âÆ×Éϵĺ¯ÊýËõ·Å¡££¨B£©ÁùÖÖ²»Í¬Á¿×ÓµãÉ«É¢µÄÎüÊպͷ¢Éä¡£ºÚÏß±íʾ 510-nm ·¢ÉäÁ¿×ÓµãµÄÎüÊÕ¡£
▐ Ó«¹âÎȶ¨ÐÔ¸ß
Á¿×ÓµãÓÉÓÚÆä¶ÀÌصľ§Ìå½á¹¹¾ßÌ弫¸ßµÄÎȶ¨ÐÔ£¬6PEG-Ag2S QD ÔÚÁ×ËáÑλº³åÑÎË® (PBS) ÖпÉÈÜÇÒÎïÀíÎȶ¨ 10 ¸öÔÂÒÔÉÏ (ͼ 4A)¡£808 nm ¼¤·¢Ê±£¬ÔÚ 1.0-1.4 ¦Ìm NIR-II ÇøÓò±£³Ö¸ßÓ«¹â (ͼ 4B)¡£6PEG-Ag2S QD ÈÜÒºµÄ×ÏÍâ/¿É¼û/½üºìÍâÎüÊÕ¹âÆ×ÏÔʾ£¬Ôڽ϶̲¨³¤´¦µÄÎüÊÕÔö¼Ó (ͼ 4C)¡£6PEG-Ag2S QD ÈÜÒºµÄ¹âÖ·¢¹âÓ뼤·¢ (PLE) ¹âÆ×ÏÔʾ£¬Ag2S QD µÄ·¢É伯ÖÐÔÚ 1200 nm ´¦ (ͼ 4D)£¬Ó뼤·¢Î޹ء£²â¶¨ 6PEG-Ag2S QD Á¿×ÓµãµÄÓ«¹âÁ¿×Ó²úÂÊԼΪ 15.5%[3]¡£
ͼ 4. ¾ßÓÐÖ§»¯ PEG Í¿²ãµÄ NIR-II Ag2S Á¿×Óµã[3]¡£
´ËÍ⣬²ÉÓà 808 nm ¼¤¹â¶þ¼«¹ÜÁ¬ÐøÕÕÉä 6PEG-Ag2S QD ÈÜÒº£¬²âÊÔÆä¹âÎȶ¨ÐÔ¡£NIR-II µÄ¹âÖ·¢¹â (PL) Ç¿¶ÈÔÚÇ° 200 s ÓÐËùϽµ£¬µ«ÔÚÁ¬ÐøÕÕÉä 0.5 h ºóÎȶ¨²¢±£³ÖÔÚ³õʼ PL Ç¿¶ÈµÄ 50% ÒÔÉÏ¡£Ó«¹âÐźÅÖµ¿É±£Áô 3 ÄêÒÔÉÏ¡£
Ò»°ãÀ´½²£¬°©Ö¢ÖÎÁÆЧ¹ûºÍÕï¶Ï³ÉÏñ¹¦Äܶ¼¿ÉÒÔͨ¹ýÒ»¸ö¾ßÓи߶ȶ๦ÄÜÐԵĵ¥ÔØÄÉÃ׽ṹϵͳÀ´ÊµÏÖ¡£ÄÉÃ×ÔØÌå±ØÐë¾¹ýÊʵ±µÄÉè¼Æ£¬Ê¹ÆäÄܹ»·½±ãµØ×°ÔØÒÔ½øÐÐÒ©Îï¿ØÖÆÊÍ·Å£¬±íÏÖ³ö¸üºÃµÄѪҺѻ·ºÍ¸ü¸ßµÄÉúÎïÀûÓöȣ¬²¢Èƹý¶àÒ©ÄÍÒ©»úÖÆ¡£Í¼ 5 ±íʾÖÎÁÆÐÔÔØÌåµÄ±ê×¼½á¹¹¼°Æä°ÐÏòÅäÌåϸ°û´©Í¸ÅäÌåÄÉÃ×Á£×Ó (³ÉÏñ/¼ì²â) ÖÎÁÆ×é¼þ¾ÛºÏÎï¡£
ͼ 5. ¾µäÁ¿×Óµã×÷ΪÖÎÁÆÔØÌåµÄÄ£ÐÍ[1]¡£
¾ßÓв»Í¬¼¸ºÎÐÎ×´±íʾµÄËùÓпÉÄܵĸ½×ÅÎ¼´ÂÌÉ«Ó«¹âÇò×÷Ϊ¼ì²â×é¼þ (ÄÉÃ׿ÅÁ£ [NPs] µÄÎÞÇÖÈëÐÔ³ÉÏñ)£¬°ÐÏòÅäÌåÈ翹Ì壬ëÄ£¬×ªÒƵ°°×£¬Ò¶Ëá (ÌÝÐÎÍ·»ùÍÅ)£¬ÖÎÁÆ×é¼þÈçºËËᣬҩÎÈÈÒ©£¬¹âÃô¼Á (ÐÇÐÎÍ·»ùÍÅ)£¬Ï¸°û´©Í¸ÅäÌ壬È缫ÐԺͷǼ«ÐÔ°±»ùËᣬÊÊÌå (¼ýÍ·»ùÍÅ)£¬ÒÔ¼°Ö÷ÒªÓɾÛÒÒ¶þ´¼£¬µ°°×ÖʺÍÆϾÛÌÇ°ü¹üµÄ¾ÛºÏÎï¡£
×¢Ò⣺ÏàͬµÄ¼¸ºÎÐÎ×´´ú±íÏàͬÀà±ðµÄ³É·Ö£¬×÷Ϊ¶à¸ö°ÐÏòÅäÌå»ò´©Í¸ÅäÌ壬¿ÉÒÔÔÚÄÉÃ׿ÅÁ£±íÃ湦ÄÜ»¯£¬ÓÃÓÚ¶à·ӦÓᣲ»Í¬µÄÑÕÉ«±»ÓÃÀ´Çø·Ö¡£
▐ Á¿×Óµã̽ÕëÔÚÖ×ÁöѪ¹ÜÉú³ÉÖеÄÓ¦ÓÃ
Ö×ÁöѪ¹ÜÉú³ÉÊÇÖ×ÁöµÄ±êÖ¾£¬ÔÚ²»Í¬ÀàÐ͵ÄʵÌåÁöÖÐÆÕ±é´æÔÚ£¬Èç¹ûûÓÐѪ¹ÜÉú³ÉÌṩÖ×ÁöÉú³¤ËùÐèµÄÑõÆøºÍÓªÑøÎïÖÊ£¬Ö×ÁöÖ»ÄÜÉú³¤µ½ 2-3 mm µÄÖ±¾¶£¬Òò´Ë£¬ÒÖÖÆÖ×ÁöѪ¹ÜÉú³ÉÊÇÖ×ÁöÖÎÁƵÄÒ»ÖÖÓÐЧ²ßÂÔ¡£
Chenghua Song µÈÈËÌá³öÁËÒ»ÖÖÐÂÐÍÄÉÃ×Ò©Îï (T&D@RGD-AgS)£¬½«¹ãÆ×ÄÚƤÒÖÖƼÁ TNP-470 ºÍ»¯ÁÆÒ©Îï Doxorubicin(DOX) ·â×°µ½Á×Ö¬¾ÛÒÒ¶þ´¼(PEG)-Ag2S Á¿×ÓµãÖУ¬²¢Í¨¹ý¼òµ¥µÄ×Ô×é×°¹ý³ÌÓë°ÐÏòÖ×ÁöѪ¹ÜµÄÌØÒìÐÔʶ±ðëÄ»· (Arg-Gly-Asp-d-Phe-Cys) (cRGD) ½áºÏ£¬ÐͬÖ×ÁöÖÎÁÆ¡£Í¨¹ýÓ«¹âÐźÅÖµÅÐ¶Ï T&D@RGD-Ag2S °ÐÏòÖ×ÁöѪ¹ÜµÄÄÜÁ¦[4]¡£
ͼ 6. T&D@RGD-Ag2S µÄÖ×ÁöÂö¹Üϵͳ°ÐÏò²â¶¨[4]¡£
(A) ΪÖ×Áö¹©ÑªµÄÖ×ÁöѪ¹ÜµÄÃ÷³¡ºÍ NIR-II Ó«¹âͼÏñ¡£(B) ×¢Éä T&D@RGD-Ag2S (ÉÏ) ºÍ T&D@Ag2S (ÏÂ) µÄ U87-MG ºÉÁöÂãÊóµÄ NIR-II Ó«¹âʱ³Ì¡£(C) Ëæ×Åʱ¼äµÄÍÆÒÆ£¬TBR ÓÉ NIR-II Ó«¹âÇ¿¶ÈÈ·¶¨£¬Ê¹ÓÃÒÔϹ«Ê½£ºTBR =(Ö×ÁöÇ¿¶È - ÔëÉùÇ¿¶Èƽ¾ùÖµ)/(±³¾°Ç¿¶È - ÔëÉùÇ¿¶Èƽ¾ùÖµ)¡£ËùÑ¡ÇøÓòÈçͼ B Ëùʾ¡£(D) СÊó×¢Éä T&D@RGD-Ag2S(ÉÏ) ºÍ T&D@Ag2S (ÏÂ) 24 Сʱºó»ñµÃµÄ×éÖ¯ºÍÆ÷¹ÙµÄÀëÌåÃ÷³¡ºÍÓ«¹âͼÏñ¡£
ÈçͼËùʾ£¬T&D@RGD-Ag2S ¾¾²Âö×¢Éäºó½øÈëÑ»·£¬ÔÚ U87-MG ÔØÁöÂãÊóµÄÖ×ÁöÖÜΧ£¬10 ·ÖÖÓÄڹ۲쵽 T&D@RGD-Ag2S Ç¿ÁÒµÄÓ«¹âÐźŠ(ͼ 6A)¡£Í¬Ê±£¬¹Û²ìµ½Ö×ÁöÇøÓò T&D@RGD-Ag2S »ýÀÛµÄÎȶ¨Ôö¼Ó (ͼ 6B-C)¡£¸÷ÖÖ×éÖ¯ºÍÆ÷¹ÙµÄÀëÌåͼÏñ½øÒ»²½Ö¤ÊµÁËÓë·Ç°ÐÏò×éÏà±È£¬°ÐÏò×éÖ×ÁöÖÐÄÉÃ׿ÅÁ£µÄ»ýÀÛ¸ü¸ß (ͼ 6D)£¬Õâ±íÃ÷ cRGD ÔÚÄÉÃ×ϵͳ°ÐÏòµÝËÍÖеÄÖØÒª×÷Óá£
´ËÍ⣬ÀûÓà Ag2S Á¿×Óµã½üºìÍâ II (NIR-II) Ó«¹â³ÉÏñÔλ¼à²â T&D@ RGD-Ag2S ÒÖÖÆÖ×ÁöÉú³¤ºÍ½µµÍѪ¹ÜÃܶȵÄÖÎÁÆЧ¹û¡£ÕâÖÖÖ×ÁöѪ¹Ü°ÐÏò²ßÂÔ¿ÉÒÔÀ©Õ¹ÎªÖÎÁƹ㷺Ö×ÁöµÄÒ»°ã·½·¨£¬²¢ÓÐÍûÔÚδÀ´µÄÁÙ´²Ó¦ÓÃÖеõ½Ó¦Óá£
²Î¿¼ÎÄÏ×£º
[1] Tripathi SK, et al. Quantum Dots and their Potential Role in Cancer Theranostics. Crit Rev Ther Drug Carrier Syst. 2015;32(6):461-502.
[2] Medintz IL, et al. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater. 2005 Jun;4(6):435-46.
[3] Hong G, et al. In vivo fluorescence imaging with Ag2S quantum dots in the second near-infrared region. Angew Chem Int Ed Engl. 2012 Sep 24;51(39):9818-21.
[4] Chenghua Song, et al. Enhanced Nanodrug Delivery to Solid Tumors Based on a Tumor Vasculature-Targeted Strategy. Adv. Funct. Mater. 2016, 26, 4192¨C4200. |